ProCE Banner Activity

GMMG-HD7: Phase III Trial of Isatuximab + VRd vs VRD Alone as Induction Therapy for Newly Diagnosed, ASCT-Eligible Multiple Myeloma

Slideset Download
Conference Coverage
Superior MRD negativity rates were achieved after induction with isatuximab + VRd vs VRd alone in patients with newly diagnosed multiple myeloma.

Released: December 16, 2021

Expiration: December 15, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation